Yi Hou, Xuemei Cao, Xiangnan Hu, Xinyu Li, Xiaoqin Shi, Hongying Wang, Chuan Peng, Jiayu Li, Jibin Li, Qifu Li, Chaodong Wu, Xiaoqiu Xiao
Traditional thiazolidinediones (TZDs), such as rosiglitazone, are peroxisome proliferator-activated receptor γ (PPARγ) potent agonists that can be used to treat type 2 diabetes but carry unwanted effects, including increased risk for fracture. The present work aimed to compare the insulin-sensitizing efficacies and bone-loss side effects of CMHX008, a novel TZDs-like PPARγ partial agonist, with those of rosiglitazone. A TR-FRET PPARγ competitive binding assay was used to compare the binding affinity between CMHX008 and rosiglitazone...
September 2018: Genes & Diseases